Care Coordination and Transition Strategies for CAR-T Therapy
Panelists discuss their institution’s approach to co-management and co-monitoring of (chimeric antigen receptor (CAR) -T patients, strategies to facilitate seamless transitions of care between academic centers and community practices, common challenges in the CAR -T referral process and solutions, and advice for community physicians on the timing and preparation for patient referrals.
Video content above is prompted by the following:
- Describe your institution’s approach to the co-management and co-monitoring of patients receiving CAR-T therapy, particularly in the transition back to the community setting.
- Can you share any specific strategies or tools your institution utilizes to facilitate seamless transitions of care between the academic center and community practices for CAR-T patients?
- What are the most common challenges you have encountered in the CAR-T referral process, and how have you addressed them at your institution?
- What advice would you provide to community physicians regarding the appropriate timing and preparation for referring patients for CAR-T therapy?
Considering NCCN Guidelines to Determine Maintenance Therapy Multiple Myeloma
February 15th 2025During the 66th American Society of Hematology Annual Meeting and Exposition, experts in multiple myeloma gathered to discuss the impact of maintenance therapy and minimal residual disease (MRD) in patients with newly diagnosed transplant-eligible or -ineligible multiple myeloma.
